%0期刊文章%A Justeau, Grégoire %A Bailly, Sebastien %A Gervès-Pinquié， Chloé %A Trzepizur, Wojciech %A Meslier, Nicole %A Goupil, François %A Pigeanne, Thierry %A Launois, Sandrine %A Leclair-Visonneau, Laurene %A Masson, Philippe %A Bizieux-Thaminy, Acya %A Racineux, Jean-Louis %A Gozal, David %A Gagnadoux, Frédéric %A，%D 2021 %R 10.1183/13993003.01935-2021 %J欧洲呼吸杂志%P 2101935 %X背景越来越多的证据表明阻塞性睡眠呼吸暂停(OSA)有助于癌症风险;然而，关于持续气道正压通气(CPAP)治疗对癌症发病率的影响的数据有限。我们的目的是确定与非依从性OSA患者相比，坚持CPAP治疗是否与降低全癌发病率相关。该研究依赖于卢瓦尔睡眠队列多中心研究收集的数据，这些数据与健康管理数据相关，如识别新发癌症。我们纳入了在诊断性睡眠研究之前或CPAP第一年没有癌症史的用于阻塞性睡眠呼吸暂停的CPAP患者。有记录的每晚使用CPAP至少4小时的患者被定义为坚持。停用或夜间使用CPAP少于4小时者为非坚持组。进行倾向评分逆概率治疗加权分析，以评估CPAP依从性对癌症风险的影响。结果在中位随访5.4年[四分位数范围]后，4499名患者中有437人(9.7%)发生癌症，非贴壁组有194人(10.7%)(n=1817)，贴壁组有243人(9.1%)(n=2682)。 The final weighted model showed no significant impact of CPAP adherence on all-cause cancer risk (sub distribution hazard ratio [95% confidence interval]): 0.94 [0.78; 1.14]).Conclusions Adherence to CPAP therapy in OSA patients was not associated with a reduction in all-cancer incidence. Whether adherent CPAP therapy of OSA might reduce the risk of specific cancer sites should be further evaluated.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Grégoire Justeau has nothing to disclose.Conflict of interest: S. Bailly reports Consulting fees for methodology and statistical analyses from ISRS Pays de la Loire, outside the submitted work.Conflict of interest: Chloé Gervès-Pinquié has nothing to disclose.Conflict of interest: Wojciech Trzepizur has nothing to disclose.Conflict of interest: Nicole Meslier has nothing to disclose.Conflict of interest: François Goupil has nothing to disclose.Conflict of interest: Thierry Pigeanne has nothing to disclose.Conflict of interest: Sandrine Launois has nothing to disclose.Conflict of interest: Laurene Leclair-Visonneau has nothing to disclose.Conflict of interest: Philippe Masson has nothing to disclose.Conflict of interest: Acya Bizieux-Thaminy has nothing to disclose.Conflict of interest: Jean-Louis Racineux has nothing to disclose.Conflict of interest: D. Gozal reports NIH grants outside the submitted work. All other authors have nothing to disclose.Conflict of interest: F. Gagnadoux reports support for the present manuscript from Institut Recherche en Santé Respiratoire des Pays de la Loire to University Hospital of Angers; consulting fees from NYXOAH, SEFAM and RESMED; payment or honoraria for lectures from CIDELEC, ASTEN SANTE and BOEHRINGER INGELHEIM; payment for expert testimony from BOEHRINGER INGELHEIM; support for attending meetings and/or travel from ASTEN SANTE and ACTELION; participation on a Data Safety Monitoring Board or Advisory Board for JAZZ PHARMACEUTICAL; receipt of equipment, materials, drugs, medical writing, gifts or other services from INSPIRE to University Hospital of Angers, outside the present work. %U //www.qdcxjkg.com/content/erj/early/2021/08/12/13993003.01935-2021.full.pdf